Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of the company’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $6.96, for a total value of $19,369.68. Following the completion of the sale, the chief financial officer now directly owns 60,875 shares in the company, valued at approximately $423,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Dennis Green also recently made the following trade(s):

  • On Thursday, May 17th, Kevin Dennis Green sold 73,000 shares of Cerus stock. The shares were sold at an average price of $6.42, for a total value of $468,660.00.

Shares of CERS traded down $0.04 during trading hours on Friday, reaching $6.87. 36,080 shares of the company traded hands, compared to its average volume of 1,193,045. The company has a quick ratio of 4.57, a current ratio of 5.03 and a debt-to-equity ratio of 0.29. The firm has a market cap of $958.11 million, a P/E ratio of -12.29 and a beta of 1.62. Cerus Co. has a fifty-two week low of $2.26 and a fifty-two week high of $8.05.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $15.42 million for the quarter, compared to analyst estimates of $13.58 million. Cerus had a negative return on equity of 82.60% and a negative net margin of 76.37%. The business’s revenue for the quarter was up 61.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.16) earnings per share. equities analysts expect that Cerus Co. will post -0.44 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of CERS. Bank of New York Mellon Corp boosted its stake in shares of Cerus by 2.8% during the fourth quarter. Bank of New York Mellon Corp now owns 470,437 shares of the biotechnology company’s stock valued at $1,590,000 after acquiring an additional 12,944 shares during the last quarter. Geode Capital Management LLC lifted its position in Cerus by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 990,324 shares of the biotechnology company’s stock worth $3,347,000 after buying an additional 76,592 shares during the period. Goldman Sachs Group Inc. lifted its position in Cerus by 202.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 313,247 shares of the biotechnology company’s stock worth $1,058,000 after buying an additional 209,531 shares during the period. Two Sigma Investments LP purchased a new position in Cerus during the fourth quarter worth about $249,000. Finally, Millennium Management LLC purchased a new position in Cerus during the fourth quarter worth about $2,888,000. 58.25% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on CERS shares. BidaskClub lowered Cerus from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 28th. ValuEngine raised Cerus from a “hold” rating to a “buy” rating in a report on Friday, May 4th. BTIG Research reissued a “hold” rating on shares of Cerus in a report on Wednesday, May 9th. Zacks Investment Research lowered Cerus from a “hold” rating to a “sell” rating in a report on Monday, May 14th. Finally, Cantor Fitzgerald reissued a “reduce” rating and issued a $9.00 target price on shares of Cerus in a report on Friday, July 20th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $8.13.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Recommended Story: New Google Finance Tool and Screening Stocks

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.